Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·InspireMD

Carotid stent maker InspireMD prices $37.5M offering built mostly on warrants

Most buyers took pre-funded warrants instead of shares, plus common warrants on top. The raise follows a May recall of InspireMD's CGuard Prime systems with 135 cm delivery systems.

Charted Staff2 min read
From a company announcement published Nov. 13, 2026, company announcements filed with the SEC on Nov. 12, 2026, and FDA premarket approval and recall records retrieved through openFDA
An ultrasound image of a carotid artery with an implanted stent. It does not show an InspireMD device.
An ultrasound image of a carotid artery with an implanted stent. It does not show an InspireMD device. File photo.Ciernik M / Wikimedia Commons (CC BY-SA 4.0)
Amount
$37.5M
Type
Follow-on
Company
InspireMD
Sector
Medtech
Announced
Nov. 13, 2026

InspireMD, the Miami company that sells the CGuard Prime carotid stent system, said Nov. 13 that it priced a $37.5 million underwritten public offering, and most of the investors chose warrants over stock.

The deal includes 7,342,308 shares of common stock and pre-funded warrants for another 50,350,000 shares, issued to certain investors in place of stock. Buyers also get common warrants to purchase 43,269,231 shares. Every security in the deal is being sold by InspireMD, and Lake Street Capital Markets is the sole book runner. The company did not state a per-share price in the announcement.

Why it matters: Pre-funded warrants let investors buy in now without immediately holding the shares, and the attached common warrants give them the right to buy still more later. Based on the figures in the release, buyers receive three common warrants for every four shares or pre-funded warrants they purchase: 43.3 million common warrants against 57.7 million shares and pre-funded warrants.

The terms

Underwriters have 30 days to buy up to 8,653,846 additional shares or pre-funded warrants, plus common warrants for up to 6,490,384 more shares, an option equal to 15% of the offering, to cover over-allotments. The deal was expected to close on or about Nov. 16.

InspireMD said it plans to use the net proceeds for research and development, sales and marketing, working capital and general corporate purposes. The securities are being sold off a shelf registration that the SEC declared effective in April 2025, and a preliminary prospectus supplement was filed Nov. 12.

The backstory

The FDA approved the CGuard Prime Carotid Stent System through the premarket approval pathway, application P240029, on June 23, 2025, according to the agency's database.

This year brought a setback. On May 1, InspireMD sent an urgent recall notice for CGuard Prime systems with 135 cm delivery systems, according to FDA recall records, citing the risk that the delivery system could run into high resistance or fail to deploy the stent. The notice told customers to stop using the affected units and quarantine their stock. The FDA lists six recalled product entries, with component design and selection as the root cause.

The offering announcement's list of risks includes the costs and operational fallout tied to that voluntary U.S. recall, possible claims and lawsuits, and what the company called substantial doubt regarding its ability to continue as a going concern. It also lists the company's need to raise more capital and its ability to stay in compliance with Nasdaq listing standards.

The offering came a day after InspireMD said the FDA had approved a premarket approval supplement for the CGuard Prime TransCarotid Stent System, a version with an 80 cm delivery system, for use in transcarotid artery revascularization, or TCAR, procedures. In third-quarter results released the same day, the company said it expects to submit a separate PMA supplement in December for a redesigned delivery system for the carotid artery stenting version, with a potential relaunch in the first half of 2027.

What to watch

InspireMD did not say in the announcement how much cash it had before the raise or how long the proceeds would last. The next disclosures to watch are the closing of the offering, whether the underwriters exercise their option, and the December PMA supplement for the redesigned delivery system that InspireMD said it plans to file.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.